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Purpose: This study aims to evaluate corneal endothelial changes occurring over a 3-month period after
intravitreal injections of ranibizumab in patients with wet age-related macular degeneration.
Methods: This is a prospective case series. A total of 29 patients (29 eyes) received a 0.5-mg intravitreal
injection of ranibizumab. Specular microscopy, including measurement of central corneal thickness and
endothelial cell count, was performed on each patient prior to and after completing three intravitreal
injections.
Results: All patients received three intravitreal injections and were followed up for a mean of 3 months.
There was no signiﬁcant change in corneal thickness (p ¼ 0.32) or endothelial cell density (p ¼ 0.38) after
ranibizumab injections.
Conclusion: Intravitreal ranibizumab injections (0.5 mg) have no harmful effects on corneal endothelial
cells.
Copyright © 2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Age-related macular degeneration (AMD) is the leading cause of
blindness in the elderly. Wet AMD induces growth of abnormal
blood vessels that obscure vision. Ranibizumab is widely used to
treat AMD, primarily based on the positive results of the Minimally
Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the
Treatment of Neovascular AMD (MARINA)1 and Anti-VEGF Anti-
body for the Treatment of Predominantly Classic Choroidal Neo-
vascularization in AMD (ANCHOR)2 studies, and it was approved by
the US Food and Drug Administration for this purpose in 2006.
Ranibizumab is a fragment of a recombinant, humanized mono-
clonal antibody derived from the parent antibody bevacizumab.1 It
binds to vascular endothelial growth factor (VEGF) and inhibits
VEGF signaling. Moreover, after intravitreal injection of ranibizu-
mab into rabbit eyes, the antibody was detected in the aqueous
humor and was found to reach a peak concentration of 17.9 mg/mL
3 days after drug administration.3 Furthermore, it was previously
shown that VEGF and its receptor are present in the corneal
endothelium4e6; therefore, it is reasonable to assume that ranibi-
zumab may inﬂuence VEGF function in the corneal endothelium.ave no conﬂicts of interest.
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ciety of Taiwan. Published by ElseBesides, several cases of acute intraocular inﬂammation after
intravitreal injections of ranibizumab have been reported.1,2 Hence,
there are some questions regarding the safety of intravitreal rani-
bizumab injections. The purpose of this study is to evaluate the
effects of intravitreal ranibizumab on corneal endothelium in order
to ascertain the safety of ranibizumab for the treatment of wet
AMD.
2. Methods
All study protocols were approved by the Institutional Review
Board of China Medical University Hospital, Taichung, Taiwan. The
intravitreal ranibizumab injection method was explained to all
patients and informed consent was obtained prior to commencing
the study. The study adhered to the principles of the Declaration of
Helsinki.
This investigation was a prospective analysis of central corneal
thickness and endothelial cell count in patients who were diag-
nosed with wet AMD and received 0.5 mg intravitreal injections of
ranibizumab (10 mg/mL, 0.23 mL/vial) between February 2012 and
December 2012 at China Medical University Hospital in Taiwan.
We included all patients with wet AMD who received intra-
vitreal injections of ranibizumab and excluded those who had poor
corneal conditions, such as endothelial cell counts <1000 cells/
mm2, cytomegalovirus endotheliitis, herpes infection, endothelial
dystrophy, and any other keratopathy or corneal disorder. All
intravitreal ranibizumab injections were administered usingvier Taiwan LLC. All rights reserved.
Table 2
Effects of intravitreal ranibizumab injections on corneal endothelium 3months after
treatment in pseudophakic patients.
N ¼ 20 Preinjection 3 mo postinjection p
Corneal thickness (mm) 556.1 553.56 0.73
Endothelial cell density (cells/mm2) 2233.22 2465.89 0.28
Table 3
Effects of intravitreal ranibizumab injections on corneal endothelium 3months after
treatment in phakic patients.
N ¼ 9 Preinjection 3 mo postinjection p
Corneal thickness (mm) 543.7 540.35 0.29
Endothelial cell density (cells/mm2) 2481.5 2506.9 0.83
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anesthetic with a mixture of lidocaine hydrochloride and bupiva-
caine hydrochloride, anterior chamber paracentesis was performed
to release the intraocular pressure. Intravitreal injection of 0.5 mg
of ranibizumab was administered through the pars plana using a
30-gauge needle. The patients returned to the outpatient clinic for
evaluation by an ophthalmologist 1 day after intravitreal injection.
They received monthly intravitreal injections of ranibizumab for 3
consecutive months; the follow-up period was 3 months after the
ﬁrst injection. Corneal endothelial cell density (ECD) and thickness
were measured using noncontact specular microscopy (SP 2000P;
Topcon Corp., Tokyo, Japan) on the day prior to injection and at
more than 3 months after the ﬁnal injection, to evaluate the effects
of ranibizumab on the corneal endothelium. Differences in corneal
endothelium prior to and after the injections were statistically
analyzed using a paired t test. A p value of <0.05 was considered to
be statistically signiﬁcant.3. Results
A total of 29 eyes of 29 patients (18 men and 11 women) were
treated with ranibizumab injections. All patients were diagnosed
with wet AMD and received three consecutive injections at 1-
month intervals.
Corneal thickness was 547.55 mm prior to the injections and
544.45 mm after the injections (p ¼ 0.32); the ECD was
2404.45 cells/mm2 prior to the injections and 2494.17 3 cells/mm2
months after the injections (p ¼ 0.38; Table 1). There was no dif-
ference in ECD prior to intravitreal ranibizumab injection and
3 months after three consecutive injections. Of the 29 eyes, nine
were pseudophakic and 20 were phakic. In patients with pseudo-
phakia (Table 2), the corneal thickness was 556.11 mm prior to the
injections and 553.56 mm after the injections (p ¼ 0.73), and the
ECD was 2233.22 cells/mm2 prior to the injections and
2465.89 cells/mm2 3 months after the injections (p ¼ 0.29). In pa-
tients with phakic lenses (Table 3), the corneal thickness was
543.7 mm prior to the injections and 540.35 mm after the injections
(p¼ 0.29), and the ECDwas 2481.5 cells/mm2 prior to the injections
and 2506.9 cells/mm2 3 months after the injections (p ¼ 0.83). No
difference was observed between patients with phakic or pseudo-
phakic lenses with respect to ECD or corneal thickness. Routine
follow-up by slit-lamp examination on the day after intravitreal
injection revealed no cases of acute intraocular inﬂammation.4. Discussion
Results of this study revealed no signiﬁcant change in the
corneal endothelium following intravitreal ranibizumab injections.
In a previous study, both bevacizumab and ranibizumab were
detected in the aqueous humor, which persisted for more than
1 month. In addition, there are anti-VEGF receptors in
endothelium.4e7 In a previous study, Chiang et al8 revealed that 2.5-
mg intravitreal injections of bevacizumab did not elicit harmful
effects on the corneal endothelium. However, Wickremasinghe
et al9 and Sato et al10 observed that 1.49e14.3% of patients who
received intravitreal bevacizumab injections developed acuteTable 1
Effects of intravitreal ranibizumab injections on corneal endothelium 3months after
treatment.
N ¼ 29 Preinjection 3 mo postinjection p
Corneal thickness (mm) 547.55 544.45 0.32
Endothelial cell density (cells/mm2) 2404.45 2494.17 0.38intraocular inﬂammation. Bevacizumab is a 149 kDa full-length
monoclonal antibody with two antigen-binding domains,
whereas ranibizumab is a 48 kDa Fab fragment that has only one
binding domain; the latter has a smaller molecular weight, and
thus penetrates into the retina more easily and shows increased
binding afﬁnity toward VEGF.3 Therefore, we assume that ranibi-
zumab may also easily penetrate into the anterior chamber from
the vitreous cavity. Furthermore, the rate of severe uveitis following
intravitreal ranibizumab injection was reported to range from 0.7%
to 1.3% in Phase III studies,1,2 and the Comparison of AMD Treat-
ments (CATT) study showed that bevacizumab and ranibizumab
had similar effects with respect to the treatment of wet AMD.11
Although bevacizumab is broadly used for the treatment of neo-
vascular AMD, this has primarily been an off-label use. However, as
ranibizumab is clinically approved for the treatment of AMD, there
is a trend toward increased use of this product in clinical condi-
tions.1,2,11 Therefore, the effects of this product on the corneal
endothelium warrant investigation.
The present study demonstrated that there was no statistically
signiﬁcant difference in corneal endothelial cell count 3 months
after 0.5 mg intravitreal injections of ranibizumab in patients with
wet AMD. Therefore, we conclude that these injections have no
harmful short-term effects. Moreover, routine follow-up by slit-
lamp examinations on the day following intravitreal injections
revealed no acute intraocular inﬂammation or corneal edema,
which further indicates that ranibizumab did not affect the corneal
endothelium. Perez-Rico et al12 evaluated the toxicity of 0.5 mg of
ranibizumab on corneal endothelial cells by evaluating the ECD,
coefﬁcient of variation of the cell size, and percentage of the hex-
agonal cells. They found no harmful effects. Our results are in
concordance with other studies that revealed that 0.5 mg intra-
vitreal injections of ranibizumab have no negative effects on the
corneal endothelium.12,13
In conclusion, the results presented herein indicate that 0.5 mg
intravitreal injections of ranibizumab do not induce corneal
endothelial cell changes up to 3 months after injection.References
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